Allied（ALID）株式概要大麻会社であるアライド社は、米国でヘンプ由来の大麻製品の開発、製造、販売を行っている。 詳細ALID ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬過去 1 年間で収益は387.3%増加しましたリスク分析株式の流動性は非常に低い 最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( $117 )収益が 100 万ドル未満 ( $105K )+1 さらなるリスクすべてのリスクチェックを見るALID Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.00000199.9% 割安 内在価値ディスカウントEst. Revenue$PastFuture-20m216k2016201920222025202620282031Revenue US$104.8kEarnings US$15.3kAdvancedSet Fair ValueView all narrativesAllied Corp. 競合他社AmeriCannSymbol: OTCPK:ACANMarket cap: US$24.4kMarizymeSymbol: OTCPK:MRZMMarket cap: US$131.0GB SciencesSymbol: OTCPK:GBLXMarket cap: US$158.8kEcofibreSymbol: OTCPK:EOFB.FMarket cap: US$366.6k価格と性能株価の高値、安値、推移の概要Allied過去の株価現在の株価US$0.00000152週高値US$0.01652週安値US$0.000001ベータ-0.721ヶ月の変化0%3ヶ月変化0%1年変化-99.90%3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Feb 08+ 1 more updateAllied Corp. Announces Resignation of Calum Hughes as DirectorOn February 3, 2025 but effective January 30, 2025, Calum Hughes resigned as a Director of the Allied Corp.お知らせ • Nov 30Allied Corp. announced delayed annual 10-K filingOn 11/29/2024, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jul 17Allied Corp. announced delayed 10-Q filingOn 07/16/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 16Allied Corp. announced delayed 10-Q filingOn 04/15/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 30Allied Corp. Announces Resignation of Santiago Ribero as DirectorAllied Corp. announced that effective March 20, 2024 Santiago Ribero resigned as a Director of the company Mr. Ribero has moved to the United States and has taken a position in the banking industry, but will continue to have an active role with the Company.お知らせ • Dec 01Allied Corp. announced delayed annual 10-K filingOn 11/30/2023, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Feb 08+ 1 more updateAllied Corp. Announces Resignation of Calum Hughes as DirectorOn February 3, 2025 but effective January 30, 2025, Calum Hughes resigned as a Director of the Allied Corp.お知らせ • Nov 30Allied Corp. announced delayed annual 10-K filingOn 11/29/2024, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jul 17Allied Corp. announced delayed 10-Q filingOn 07/16/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 16Allied Corp. announced delayed 10-Q filingOn 04/15/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 30Allied Corp. Announces Resignation of Santiago Ribero as DirectorAllied Corp. announced that effective March 20, 2024 Santiago Ribero resigned as a Director of the company Mr. Ribero has moved to the United States and has taken a position in the banking industry, but will continue to have an active role with the Company.お知らせ • Dec 01Allied Corp. announced delayed annual 10-K filingOn 11/30/2023, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jul 16Allied Corp. announced delayed 10-Q filingOn 07/14/2023, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 19Allied Corp. announced delayed 10-Q filingOn 01/18/2023, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 29Allied Corp. announced delayed annual 10-K filingOn 11/28/2022, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 24Allied Corp Receives The Brazilian Health Regulatory Agency Approval for Brazilian ImportAllied Corp. announced that following an extensive regulatory review, it has received ANVISA approval for Brazilian importation. On April 27th, 2022 Allied announced the signing of a forward purchase agreement for the manufacturing and sell-through of medical products destined for Brazil. On June 09, 2022 Allied further announced the successful initial shipment for this forward purchase agreement. By way of this announcement, Allied has now obtained ANVISA approval for these transactions. The Brazilian Health Regulatory Agency (ANVISA) controls the importation of medical products to the Brazilian market. ANVISA’s role is to promote the protection of the population’s health by executing sanitary control of the production, marketing and use of products and services subject to health regulation, including related environments, processes, ingredients and technologies, as well as the control of ports, airports and borders. Allied has now met the required regulatory requirements for Brazilian ANVISA and is now importing into the Brazilian medical market.お知らせ • Jul 15Allied Corp. announced delayed 10-Q filingOn 07/14/2022, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 15Allied Corp. announced delayed 10-Q filingOn 04/14/2022, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 06Allied Corp Commends Colombian Government for Announcing the Final Approval of the Regulations for the Export of Cannabis from ColombiaAllied Corp. commended the Colombian Government for the final approval of Regulation 227 (the "Regulation") which describes the technical guidelines regarding the export of cannabis flower from Colombia. On July 23, 2021, the President of Colombia, President Ivan Duque, signed Decree 811 lifting the prohibition on exportation of dried cannabis flower from Colombia. In October 2021, Allied was asked to provide first comment on the Regulation and then in November 2021, second comment. On February 20, 2022, Regulation 227 was officially announced by the President of Colombia introducing the practical regulations and implementation plan for the export of cannabis flower. On April 01, 2022, the Colombian Government has released final approval of the technical guidelines necessary for the export of cannabis flower. This, among other important advances, will enable Allied to begin exporting dried cannabis flower internationally to countries where it is legal to do so. Of note, the United States still has a legal limit of 0.3% THC. While only a few Colombian companies have been able to successfully export cannabis derivatives such as CBD distillate and isolate, up until now, the export of dried flower from Colombia has been prohibited. Allied has successfully shipped to several international markets and will now be submitting for multiple export requests for dried cannabis flower destined for international markets.お知らせ • Jan 16Allied Corp. announced delayed 10-Q filingOn 01/14/2022, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 30Allied Corp. announced delayed annual 10-K filingOn 11/29/2021, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 21Allied Corp. Announces Approval of Second CBD Isolate Import Permit for Australia and Submits Application for the Import of Dried CannabisAllied Corp. announced that it has received approval of a second import permit for export of CBD isolate produced at Allied’s Colombian campus that is destined for the Australian market. In addition to this, through its Australian partner, Allied has submitted its first import permit to the Australian Department of Health for the import of dried cannabis flower. This dried flower import permit application is the first of its kind for Allied. This import application was made following the announcement made by the President of Colombia announcing the expansion of Colombia’s ability to export dried cannabis flower. Allied’s Australian partner has been in the pharmaceutical, medical device and medical supply for 30 years including being a Prime Vendor to the ADF (Australian Defense Forces) for 10 of those years. This has included supplying small medical devices, consumable and pharmaceutical needs (on and off continent). Over the past 4 years, Allied’s Australian partner has become expert in, and has supported the Australian government in, growing innovative new markets including: unregistered specialty medicines, devices for reduction of nicotine addiction, Psilocybin products, medicinal cannabis with secure storage and nationwide distribution as well as export and import.お知らせ • Aug 26Allied Corp. Initiates Additional Shipment of 200kgs of CBD Distillate From Colombia to Nevada, United StatesAllied Corp. announced that it has received approval from the Colombian Ministry of Justice to initiate a shipment of 200kgs of extracted CBD distillate product (containing less than 0.3% THC) to the United States. This shipment is specifically destined for the State of Nevada, which includes Las Vegas and Reno, and represents Allied’s shipment of CBD distillate product (containing less than 0.3% THC) to date. Allied is focusing on the State of Nevada, among other States, because believe a demonstration of the ability to produce CBD (containing less than 0.3% THC) in Colombia and its shipment to the United States, will allow them to be better positioned for US national legalization if and when it occurs. Given that the city of Las Vegas gets approximately 42 million visitors yearly (according to the Las Vegas Convention and Visitors Authority), there will be a large population of consumers coming from all over the world that will have exposure to CBD (containing less than 0.3% THC) products.お知らせ • Jul 16+ 1 more updateAllied Corp. announced delayed 10-Q filingOn 07/15/2021, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 15Allied Corp. announced a financing transactionAllied Corp. (OTCPK:ALID) announced that it will receive $525,000 in funding on June 14, 2021. The company will issue common stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. The minimum investment accepted from any outside investor is $10,000.お知らせ • May 19+ 3 more updatesAllied Corp. announced that it has received $0.575 million in fundingOn May 18, 2021, Allied Corp. closed the transaction. The transaction included participation from six investors.お知らせ • Apr 16Allied Corp. announced delayed 10-Q filingOn 04/15/2021, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 19Allied Corp. Files Provisional Patent for Psilocybin Therapeutic Invention Seeking Drug Indication for Mental Health Depression and Anxiety ApplicationsAllied Corp. announced that it has submitted a provisional patent for the Allied therapeutic formulation and treatment regimen involving a prescription drug followed by a prophylactic daily drug formulation. These two products together administered under a novel treatment regimen is intended to be tested through the Allied clinical trial infrastructure to seek a drug indication for general depression and anxiety. This provisional patent contemplates the full scope treatment of general depression and anxiety with a proprietary Rx prescription medication followed by a daily prophylactic dose of proprietary medicinal compositions. This includes a proprietary dosing and therapeutic regimen of psilocybin, additional functional mushrooms and cannabinoid therapeutics. Among the various aspects of the present invention contemplated in the provisional patent sub- mission are compositions, formulations, methods for modulating endocannabinoid system activity, for modulating neuro-steroid biosynthesis, and for modulating neurotransmission, and methods for treating mental health disorders and improving mental health, using synergistic combinations of psilocybin, cannabinoids, and other active agents, provided in distinct daily dosing regimens. The content contemplated in the provisional patent submission describes the real world pharmaceutical formulations that Allied intends to research via human clinical trials in order to seek a drug indication.お知らせ • Mar 10Allied Corp. Receives ICA Approval for Psychoactive THC StrainsAllied Corp. announced that its subsidiary Allied Colombia SAS has received approval from the Colombian Institute of Agriculture for the cultivation of its proprietary psychoactive cannabis strains. All 10 strains were approved and have passed all of the ICA requirements to be able to cultivate the high THC plants. Allied will now apply for a psychoactive export quota under the Colombian regime. The psychoactive seed evaluation approval was over a year-long process that began with the registration of the ten (10) novel psycho active (THC based) Allied strains with the national cultivar registry. Each strain was then germinated into plantlets in Allied’s scientific cultivation center in Colombia. Following germination, the plants entered into field trials that included rigorous data collection, analysis and phenotyping of the strains while in the vegetation life cycle. During this time, the strains were provided with propriety nutrients, handled with standard operating procedures and guided towards the plant flowering phase. Proprietary nutrients and procedures were also adhered to during the flowering phase and detailed batch record audit data were diligently collected during every day of the plant life cycle. Following flowering, the plants were harvested and tested for cannabinoid profiles and quality assurance testing parameters. The harvested material was then sent to an accredited laboratory for testing was and tested by high performance liquid chromatography (HPLC) testing methods. The lab results showed a higher cannabinoid profile from being grown in the Colombian climate when compared to the same strains grown in North American climate. The lab results, batch records and procedural archives were also submitted to the Colombian Institute of Agriculture and a day-long presentation was provided by Allied’s team.お知らせ • Jan 15Allied Corp. announced delayed 10-Q filingOn 01/14/2021, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 26Allied Corp. (OTCPK:ALID) entered into a letter of intent to acquire Pacific Sun Fungi.Allied Corp. (OTCPK:ALID) entered into a letter of intent to acquire Pacific Sun Fungi on December 20, 2020.お知らせ • Dec 13Allied Corp. Goes Live with US Sales of Equilibrium Bio CBD Electrolyte Replacement Rehydration DrinksAllied Corp. announced the completion of the first manufacturing run of Hydro Sport CBD-infused rehydration drinks from Allied’s latest brand Equilibrium Bio. As well, these drinks have also been produced for the Tactical Relief™ branding as Tactical Hydration electrolyte replacement and rehydration drink products. The first Equilibrium Bio products known as Hydro Sport are available for purchase on e-commerce platforms and have also been shipped to national retail buyers throughout the US. The first manufactured batch encompasses six unique product SKUs (stock-keeping units). The CBD-infused drink pouches come in three flavors: Lemon Lime, Berry Fresh and Orange Burst. The all-natural flavoring and ingredients in the drinks include: Filtered Water, CBD 20 (mg), CBD, CBG, Sodium Citrate, Citric Acid, Sea Salt, Natural Flavor, Tripotassium Citrate, Vitamin B Complex, Ascorbic Acid (Vitamin C), Sucralose, Acesulfame Potassium and Beta Carotene for color. The Hydro Sport drinks are the first electrolyte replacement drink to offer CBD, CBG and CBN and have been designed to aide athletes to relax and recover. Equilibrium Bio™ is a lifestyle brand that is focused on everything athletic. From High Intensity Interval Training workouts to Ironman races to general athletic consumers, Equilibrium Bio products are there with the athlete along the entire competitive journey. Rehydration and electrolyte replacement is a primary focus for this brand and its products.お知らせ • Dec 01Allied Corp. announced delayed annual 10-K filingOn 11/30/2020, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 17Allied Signs Monthly Recurring Purchase Order for Sale of Proprietary Cannabis ProductAllied Corp. has now signed its first monthly recurring purchase order. Allied is an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues. Allied announced the signing of its first monthly recurring forward purchase agreement with Mistral Consulting Group for the sale of Allied’s proprietary cannabis products. The agreement consists of a monthly recurring purchase order of extracted cannabis products in quantities scaling from 1-5kgs per month to 50kgs per month for each month between November 2020 and March 2021. Both parties have written into the agreement that they anticipate this monthly quantity to scale to larger quantities beyond the 50kgs per month. The term of the agreement is set for a 12 month recurring monthly purchase cycle with the option to continue for another 5 years beyond the first 12 months. The product under the purchase order will meet quality assurance standards such as the testing parameters contained in the European Pharmacopeia standards for the US and European markets, GACP (Good Agricultural Collection Practice) Standards, and GPP (Good Production Practices) to meet the standards for the Canadian market. The achievement of these criteria will be evidenced by the detailed batch records and certificates of analysis laboratory testing results that Allied performs for each harvested batch.お知らせ • Oct 08Allied Corp. Signs Definitive Agreement for the Launch of CBD-Infused Electrolyte Replacement Drink for Veterans and AthletesAllied Corp. announced the signing of a definitive agreement to launch a new CBD-infused electrolyte replacement drink with the Cannabis company Reef Drink Company. The first product to be produced under the Agreement will be a CBD-infused electrolyte and rehydration drink targeted at veteran and first responders as an extension of the Tactical Relief™ brand. This product will be called Tactical Hydration and launched under the Tactical Relief™ brand. In addition to this, a second Allied Corp. brand has now been launched called Equilibrium Bio. As with the Tactical Relief™ brand, the Equilibrium Bio brand is owned, managed and supported by Allied Corp. This brand will represent health and wellness products targeted at both male and female athletic consumers. The first product will be called “Hydration Blast” by Equilibrium Bio. All produced and supported by Allied. Tactical Hydration and Hydration Blast products will provide a CBD-infused drink for rehydration with sodium citrate electrolyte replacement supplements for athletic and veteran consumers. Both the Tactical Relief and Equilibrium Bio drinks will be available in fruit punch, lemon lime and orange flavors. Allied has additional products in the Equilibrium Bio and Tactical Relief product pipeline. Allied anticipates the first 15,000 sample drink products being ready for wholesale purchasers within October 2020. From these 15,000 sample products, it will be pursuing purchase orders and national distribution.お知らせ • Jul 30Allied Corp. (OTCPK:ALID) completed the acquisition of Medicolombia’s Cannabis S.A.S. from Dorson Commercial Corp. for $7.6 million.Allied Corp. (OTCPK:ALID) entered into a share purchase agreement to acquire Medicolombia’s Cannabis S.A.S. from Dorson Commercial Corp. for $7.3 million on August 29, 2019. Pursuant to the agreement, Allied will acquire all of the issued and outstanding shares of Medicolombia’s Cannabis in exchange for $0.7 million and 4.5 million shares of Allied. At August 31, 2019, Allied had paid a $0.7 million deposit and advanced funds for operations. At August 31, 2019, $1.16 million had been advanced to Dorson Commercial Corp. and was recorded as a prepaid and deposit. At November 30, 2019, the $1.01 million had been advanced to Dorson Commercial Corp. and was recorded as an advance. Allied Corp. (OTCPK:ALID) completed the acquisition of Medicolombia’s Cannabis S.A.S. from Dorson Commercial Corp. for $7.6 million on February 17, 2020. During the period leading up to the acquisition, Allied Corp. made additional advances to Dorson Commercial Corp. and Medicolombia’s Cannabis S.A.S. totaling $0.3 million.株主還元ALIDUS PharmaceuticalsUS 市場7D0%-12.9%-0.9%1Y-99.9%34.9%24.4%株主還元を見る業界別リターン: ALID過去 1 年間で34.9 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: ALIDは、過去 1 年間で24.4 % のリターンを上げたUS市場を下回りました。価格変動Is ALID's price volatile compared to industry and market?ALID volatilityALID Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.0%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.1%安定した株価: ALIDの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のALIDのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aMichael Mosesallied.health大麻会社アライド・コーポレーションは、米国でヘンプ由来の大麻製品の開発、製造、販売を行っている。アライド・コロンビアとアライド・コーポレーションの2つのセグメントで事業を展開している。同社は、ヘンプベースのCBD自然健康製品、美容・スキンケア製品、食品・飲料などの大麻関連製品を提供している。また、5-HT2受容体および生理学的経路の標的機能による心的外傷後ストレス障害および関連する精神疾患の治療薬として、アリッド10およびアリッド11を開発している。アライド社はカナダのケロウナに本社を置いている。もっと見るAllied Corp. 基礎のまとめAllied の収益と売上を時価総額と比較するとどうか。ALID 基礎統計学時価総額US$117.00収益（TTM）-US$3.92m売上高(TTM)US$104.81k0.0xP/Sレシオ0.0xPER（株価収益率ALID は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ALID 損益計算書（TTM）収益US$104.81k売上原価US$431.37k売上総利益-US$326.56kその他の費用US$3.59m収益-US$3.92m直近の収益報告Nov 30, 2024次回決算日該当なし一株当たり利益（EPS）-0.033グロス・マージン-311.57%純利益率-3,739.91%有利子負債／自己資本比率-86.2%ALID の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/15 11:49終値2026/03/02 00:00収益2024/11/30年間収益2024/08/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Allied Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 08+ 1 more updateAllied Corp. Announces Resignation of Calum Hughes as DirectorOn February 3, 2025 but effective January 30, 2025, Calum Hughes resigned as a Director of the Allied Corp.
お知らせ • Nov 30Allied Corp. announced delayed annual 10-K filingOn 11/29/2024, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jul 17Allied Corp. announced delayed 10-Q filingOn 07/16/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 16Allied Corp. announced delayed 10-Q filingOn 04/15/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 30Allied Corp. Announces Resignation of Santiago Ribero as DirectorAllied Corp. announced that effective March 20, 2024 Santiago Ribero resigned as a Director of the company Mr. Ribero has moved to the United States and has taken a position in the banking industry, but will continue to have an active role with the Company.
お知らせ • Dec 01Allied Corp. announced delayed annual 10-K filingOn 11/30/2023, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 08+ 1 more updateAllied Corp. Announces Resignation of Calum Hughes as DirectorOn February 3, 2025 but effective January 30, 2025, Calum Hughes resigned as a Director of the Allied Corp.
お知らせ • Nov 30Allied Corp. announced delayed annual 10-K filingOn 11/29/2024, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jul 17Allied Corp. announced delayed 10-Q filingOn 07/16/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 16Allied Corp. announced delayed 10-Q filingOn 04/15/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 30Allied Corp. Announces Resignation of Santiago Ribero as DirectorAllied Corp. announced that effective March 20, 2024 Santiago Ribero resigned as a Director of the company Mr. Ribero has moved to the United States and has taken a position in the banking industry, but will continue to have an active role with the Company.
お知らせ • Dec 01Allied Corp. announced delayed annual 10-K filingOn 11/30/2023, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jul 16Allied Corp. announced delayed 10-Q filingOn 07/14/2023, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 19Allied Corp. announced delayed 10-Q filingOn 01/18/2023, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 29Allied Corp. announced delayed annual 10-K filingOn 11/28/2022, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 24Allied Corp Receives The Brazilian Health Regulatory Agency Approval for Brazilian ImportAllied Corp. announced that following an extensive regulatory review, it has received ANVISA approval for Brazilian importation. On April 27th, 2022 Allied announced the signing of a forward purchase agreement for the manufacturing and sell-through of medical products destined for Brazil. On June 09, 2022 Allied further announced the successful initial shipment for this forward purchase agreement. By way of this announcement, Allied has now obtained ANVISA approval for these transactions. The Brazilian Health Regulatory Agency (ANVISA) controls the importation of medical products to the Brazilian market. ANVISA’s role is to promote the protection of the population’s health by executing sanitary control of the production, marketing and use of products and services subject to health regulation, including related environments, processes, ingredients and technologies, as well as the control of ports, airports and borders. Allied has now met the required regulatory requirements for Brazilian ANVISA and is now importing into the Brazilian medical market.
お知らせ • Jul 15Allied Corp. announced delayed 10-Q filingOn 07/14/2022, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 15Allied Corp. announced delayed 10-Q filingOn 04/14/2022, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 06Allied Corp Commends Colombian Government for Announcing the Final Approval of the Regulations for the Export of Cannabis from ColombiaAllied Corp. commended the Colombian Government for the final approval of Regulation 227 (the "Regulation") which describes the technical guidelines regarding the export of cannabis flower from Colombia. On July 23, 2021, the President of Colombia, President Ivan Duque, signed Decree 811 lifting the prohibition on exportation of dried cannabis flower from Colombia. In October 2021, Allied was asked to provide first comment on the Regulation and then in November 2021, second comment. On February 20, 2022, Regulation 227 was officially announced by the President of Colombia introducing the practical regulations and implementation plan for the export of cannabis flower. On April 01, 2022, the Colombian Government has released final approval of the technical guidelines necessary for the export of cannabis flower. This, among other important advances, will enable Allied to begin exporting dried cannabis flower internationally to countries where it is legal to do so. Of note, the United States still has a legal limit of 0.3% THC. While only a few Colombian companies have been able to successfully export cannabis derivatives such as CBD distillate and isolate, up until now, the export of dried flower from Colombia has been prohibited. Allied has successfully shipped to several international markets and will now be submitting for multiple export requests for dried cannabis flower destined for international markets.
お知らせ • Jan 16Allied Corp. announced delayed 10-Q filingOn 01/14/2022, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 30Allied Corp. announced delayed annual 10-K filingOn 11/29/2021, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 21Allied Corp. Announces Approval of Second CBD Isolate Import Permit for Australia and Submits Application for the Import of Dried CannabisAllied Corp. announced that it has received approval of a second import permit for export of CBD isolate produced at Allied’s Colombian campus that is destined for the Australian market. In addition to this, through its Australian partner, Allied has submitted its first import permit to the Australian Department of Health for the import of dried cannabis flower. This dried flower import permit application is the first of its kind for Allied. This import application was made following the announcement made by the President of Colombia announcing the expansion of Colombia’s ability to export dried cannabis flower. Allied’s Australian partner has been in the pharmaceutical, medical device and medical supply for 30 years including being a Prime Vendor to the ADF (Australian Defense Forces) for 10 of those years. This has included supplying small medical devices, consumable and pharmaceutical needs (on and off continent). Over the past 4 years, Allied’s Australian partner has become expert in, and has supported the Australian government in, growing innovative new markets including: unregistered specialty medicines, devices for reduction of nicotine addiction, Psilocybin products, medicinal cannabis with secure storage and nationwide distribution as well as export and import.
お知らせ • Aug 26Allied Corp. Initiates Additional Shipment of 200kgs of CBD Distillate From Colombia to Nevada, United StatesAllied Corp. announced that it has received approval from the Colombian Ministry of Justice to initiate a shipment of 200kgs of extracted CBD distillate product (containing less than 0.3% THC) to the United States. This shipment is specifically destined for the State of Nevada, which includes Las Vegas and Reno, and represents Allied’s shipment of CBD distillate product (containing less than 0.3% THC) to date. Allied is focusing on the State of Nevada, among other States, because believe a demonstration of the ability to produce CBD (containing less than 0.3% THC) in Colombia and its shipment to the United States, will allow them to be better positioned for US national legalization if and when it occurs. Given that the city of Las Vegas gets approximately 42 million visitors yearly (according to the Las Vegas Convention and Visitors Authority), there will be a large population of consumers coming from all over the world that will have exposure to CBD (containing less than 0.3% THC) products.
お知らせ • Jul 16+ 1 more updateAllied Corp. announced delayed 10-Q filingOn 07/15/2021, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 15Allied Corp. announced a financing transactionAllied Corp. (OTCPK:ALID) announced that it will receive $525,000 in funding on June 14, 2021. The company will issue common stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. The minimum investment accepted from any outside investor is $10,000.
お知らせ • May 19+ 3 more updatesAllied Corp. announced that it has received $0.575 million in fundingOn May 18, 2021, Allied Corp. closed the transaction. The transaction included participation from six investors.
お知らせ • Apr 16Allied Corp. announced delayed 10-Q filingOn 04/15/2021, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 19Allied Corp. Files Provisional Patent for Psilocybin Therapeutic Invention Seeking Drug Indication for Mental Health Depression and Anxiety ApplicationsAllied Corp. announced that it has submitted a provisional patent for the Allied therapeutic formulation and treatment regimen involving a prescription drug followed by a prophylactic daily drug formulation. These two products together administered under a novel treatment regimen is intended to be tested through the Allied clinical trial infrastructure to seek a drug indication for general depression and anxiety. This provisional patent contemplates the full scope treatment of general depression and anxiety with a proprietary Rx prescription medication followed by a daily prophylactic dose of proprietary medicinal compositions. This includes a proprietary dosing and therapeutic regimen of psilocybin, additional functional mushrooms and cannabinoid therapeutics. Among the various aspects of the present invention contemplated in the provisional patent sub- mission are compositions, formulations, methods for modulating endocannabinoid system activity, for modulating neuro-steroid biosynthesis, and for modulating neurotransmission, and methods for treating mental health disorders and improving mental health, using synergistic combinations of psilocybin, cannabinoids, and other active agents, provided in distinct daily dosing regimens. The content contemplated in the provisional patent submission describes the real world pharmaceutical formulations that Allied intends to research via human clinical trials in order to seek a drug indication.
お知らせ • Mar 10Allied Corp. Receives ICA Approval for Psychoactive THC StrainsAllied Corp. announced that its subsidiary Allied Colombia SAS has received approval from the Colombian Institute of Agriculture for the cultivation of its proprietary psychoactive cannabis strains. All 10 strains were approved and have passed all of the ICA requirements to be able to cultivate the high THC plants. Allied will now apply for a psychoactive export quota under the Colombian regime. The psychoactive seed evaluation approval was over a year-long process that began with the registration of the ten (10) novel psycho active (THC based) Allied strains with the national cultivar registry. Each strain was then germinated into plantlets in Allied’s scientific cultivation center in Colombia. Following germination, the plants entered into field trials that included rigorous data collection, analysis and phenotyping of the strains while in the vegetation life cycle. During this time, the strains were provided with propriety nutrients, handled with standard operating procedures and guided towards the plant flowering phase. Proprietary nutrients and procedures were also adhered to during the flowering phase and detailed batch record audit data were diligently collected during every day of the plant life cycle. Following flowering, the plants were harvested and tested for cannabinoid profiles and quality assurance testing parameters. The harvested material was then sent to an accredited laboratory for testing was and tested by high performance liquid chromatography (HPLC) testing methods. The lab results showed a higher cannabinoid profile from being grown in the Colombian climate when compared to the same strains grown in North American climate. The lab results, batch records and procedural archives were also submitted to the Colombian Institute of Agriculture and a day-long presentation was provided by Allied’s team.
お知らせ • Jan 15Allied Corp. announced delayed 10-Q filingOn 01/14/2021, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 26Allied Corp. (OTCPK:ALID) entered into a letter of intent to acquire Pacific Sun Fungi.Allied Corp. (OTCPK:ALID) entered into a letter of intent to acquire Pacific Sun Fungi on December 20, 2020.
お知らせ • Dec 13Allied Corp. Goes Live with US Sales of Equilibrium Bio CBD Electrolyte Replacement Rehydration DrinksAllied Corp. announced the completion of the first manufacturing run of Hydro Sport CBD-infused rehydration drinks from Allied’s latest brand Equilibrium Bio. As well, these drinks have also been produced for the Tactical Relief™ branding as Tactical Hydration electrolyte replacement and rehydration drink products. The first Equilibrium Bio products known as Hydro Sport are available for purchase on e-commerce platforms and have also been shipped to national retail buyers throughout the US. The first manufactured batch encompasses six unique product SKUs (stock-keeping units). The CBD-infused drink pouches come in three flavors: Lemon Lime, Berry Fresh and Orange Burst. The all-natural flavoring and ingredients in the drinks include: Filtered Water, CBD 20 (mg), CBD, CBG, Sodium Citrate, Citric Acid, Sea Salt, Natural Flavor, Tripotassium Citrate, Vitamin B Complex, Ascorbic Acid (Vitamin C), Sucralose, Acesulfame Potassium and Beta Carotene for color. The Hydro Sport drinks are the first electrolyte replacement drink to offer CBD, CBG and CBN and have been designed to aide athletes to relax and recover. Equilibrium Bio™ is a lifestyle brand that is focused on everything athletic. From High Intensity Interval Training workouts to Ironman races to general athletic consumers, Equilibrium Bio products are there with the athlete along the entire competitive journey. Rehydration and electrolyte replacement is a primary focus for this brand and its products.
お知らせ • Dec 01Allied Corp. announced delayed annual 10-K filingOn 11/30/2020, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 17Allied Signs Monthly Recurring Purchase Order for Sale of Proprietary Cannabis ProductAllied Corp. has now signed its first monthly recurring purchase order. Allied is an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues. Allied announced the signing of its first monthly recurring forward purchase agreement with Mistral Consulting Group for the sale of Allied’s proprietary cannabis products. The agreement consists of a monthly recurring purchase order of extracted cannabis products in quantities scaling from 1-5kgs per month to 50kgs per month for each month between November 2020 and March 2021. Both parties have written into the agreement that they anticipate this monthly quantity to scale to larger quantities beyond the 50kgs per month. The term of the agreement is set for a 12 month recurring monthly purchase cycle with the option to continue for another 5 years beyond the first 12 months. The product under the purchase order will meet quality assurance standards such as the testing parameters contained in the European Pharmacopeia standards for the US and European markets, GACP (Good Agricultural Collection Practice) Standards, and GPP (Good Production Practices) to meet the standards for the Canadian market. The achievement of these criteria will be evidenced by the detailed batch records and certificates of analysis laboratory testing results that Allied performs for each harvested batch.
お知らせ • Oct 08Allied Corp. Signs Definitive Agreement for the Launch of CBD-Infused Electrolyte Replacement Drink for Veterans and AthletesAllied Corp. announced the signing of a definitive agreement to launch a new CBD-infused electrolyte replacement drink with the Cannabis company Reef Drink Company. The first product to be produced under the Agreement will be a CBD-infused electrolyte and rehydration drink targeted at veteran and first responders as an extension of the Tactical Relief™ brand. This product will be called Tactical Hydration and launched under the Tactical Relief™ brand. In addition to this, a second Allied Corp. brand has now been launched called Equilibrium Bio. As with the Tactical Relief™ brand, the Equilibrium Bio brand is owned, managed and supported by Allied Corp. This brand will represent health and wellness products targeted at both male and female athletic consumers. The first product will be called “Hydration Blast” by Equilibrium Bio. All produced and supported by Allied. Tactical Hydration and Hydration Blast products will provide a CBD-infused drink for rehydration with sodium citrate electrolyte replacement supplements for athletic and veteran consumers. Both the Tactical Relief and Equilibrium Bio drinks will be available in fruit punch, lemon lime and orange flavors. Allied has additional products in the Equilibrium Bio and Tactical Relief product pipeline. Allied anticipates the first 15,000 sample drink products being ready for wholesale purchasers within October 2020. From these 15,000 sample products, it will be pursuing purchase orders and national distribution.
お知らせ • Jul 30Allied Corp. (OTCPK:ALID) completed the acquisition of Medicolombia’s Cannabis S.A.S. from Dorson Commercial Corp. for $7.6 million.Allied Corp. (OTCPK:ALID) entered into a share purchase agreement to acquire Medicolombia’s Cannabis S.A.S. from Dorson Commercial Corp. for $7.3 million on August 29, 2019. Pursuant to the agreement, Allied will acquire all of the issued and outstanding shares of Medicolombia’s Cannabis in exchange for $0.7 million and 4.5 million shares of Allied. At August 31, 2019, Allied had paid a $0.7 million deposit and advanced funds for operations. At August 31, 2019, $1.16 million had been advanced to Dorson Commercial Corp. and was recorded as a prepaid and deposit. At November 30, 2019, the $1.01 million had been advanced to Dorson Commercial Corp. and was recorded as an advance. Allied Corp. (OTCPK:ALID) completed the acquisition of Medicolombia’s Cannabis S.A.S. from Dorson Commercial Corp. for $7.6 million on February 17, 2020. During the period leading up to the acquisition, Allied Corp. made additional advances to Dorson Commercial Corp. and Medicolombia’s Cannabis S.A.S. totaling $0.3 million.
